Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Animesh D Pardanani

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
European Journal of Haematology|June 13, 2003
Chronic basophilic leukemia: a distinct clinico-pathologic entity?Animesh D Pardanani, William G Morice, James D Hoyer, et al.
Blood|November 11, 2009
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosisKebede Hussein, Animesh D Pardanani, Daniel L Van Dyke, et al.
British Journal of Haematology|July 12, 2017
Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevanceDaniela Barraco, Sonia Cerquozzi, Curtis A Hanson, et al.
American Journal of Hematology|January 7, 2010
Phase1/-2 study of Pomalidomide in myelofibrosisRuben A Mesa, Animesh D Pardanani, Kebede Hussein, et al.
Blood Advances|August 12, 2018
Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levelsAyalew Tefferi, Maura Nicolosi, Domenico Penna, et al.
American Journal of Hematology|May 15, 2025
The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic CorrelatesMasooma S Rana, Moazah Iftikhar, Yamna Jadoon, et al.
Leukemia Research|January 3, 2009
Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocationsStephanie R Fink, Kimberly J Belongie, Sarah F Paternoster, et al.
Blood|October 11, 2014
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variantsAyalew Tefferi, Terra L Lasho, Alexander Tischer, et al.
British Journal of Haematology|December 3, 2015
ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosisAnimesh D Pardanani, Terra L Lasho, Christy Finke, et al.
Cancer|April 12, 2011
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trialRuben A Mesa, Hagop Kantarjian, Ayalew Tefferi, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
European Journal of Haematology|June 13, 2003
Chronic basophilic leukemia: a distinct clinico-pathologic entity?Animesh D Pardanani, William G Morice, James D Hoyer, et al.
Blood|November 11, 2009
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosisKebede Hussein, Animesh D Pardanani, Daniel L Van Dyke, et al.
British Journal of Haematology|July 12, 2017
Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevanceDaniela Barraco, Sonia Cerquozzi, Curtis A Hanson, et al.
American Journal of Hematology|January 7, 2010
Phase1/-2 study of Pomalidomide in myelofibrosisRuben A Mesa, Animesh D Pardanani, Kebede Hussein, et al.
Blood Advances|August 12, 2018
Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levelsAyalew Tefferi, Maura Nicolosi, Domenico Penna, et al.
American Journal of Hematology|May 15, 2025
The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic CorrelatesMasooma S Rana, Moazah Iftikhar, Yamna Jadoon, et al.
Leukemia Research|January 3, 2009
Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocationsStephanie R Fink, Kimberly J Belongie, Sarah F Paternoster, et al.
Blood|October 11, 2014
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variantsAyalew Tefferi, Terra L Lasho, Alexander Tischer, et al.
British Journal of Haematology|December 3, 2015
ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosisAnimesh D Pardanani, Terra L Lasho, Christy Finke, et al.
Cancer|April 12, 2011
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trialRuben A Mesa, Hagop Kantarjian, Ayalew Tefferi, et al.
Pageof 2